Conditional Reprogramming Inducing Clinical Cells Proliferation: New Research Tools in Tumor and Inflammatory-related Diseases

Author(s): Jie chai, Li Han, Jianbo Zhang, Dali Han, Lei Zou, Ze Zhu, Yulong Zhao, Hongliang Guo*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 22 , 2020

DOI : 10.2174/1381612826666200316155252

  Journal Home
Become EABM
Become Reviewer

Abstract:

In the era of precision medicine, establishing a patient-derived cell model is crucial, whether in vitro or in vivo. Compared to the traditional cell lines, patient-derived primary cells represent precise genetic features from specific patients, but poor proliferative activity of human primary cells restricts their popular application. Conditional reprogramming (CR) is a new cell culture technique to achieve rapid growth of patient-derived cells in vitro, making it possible to identify the individual difference and screen drugs sensitivity. In this review, we will summarize the application and limitation of CR in tumor and inflammatory-related diseases, indicating the prospect of this technique for preclinical research.

Keywords: Tumor, inflammatory-related diseases, conditional reprogramming (CR), drugs screening, cell lines, proliferative.

[1]
Liu X, Ory V, Chapman S, et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 2012; 180(2): 599-607.
[http://dx.doi.org/10.1016/j.ajpath.2011.10.036] [PMID: 22189618]
[2]
Tsao SW, Wang X, Liu Y, et al. Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim Biophys Acta 2002; 1590(1-3): 150-8.
[http://dx.doi.org/10.1016/S0167-4889(02)00208-2] [PMID: 12063178]
[3]
Abdallah BM, Haack-Sørensen M, Burns JS, et al. Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite [corrected] extensive proliferation. Biochem Biophys Res Commun 2005; 326(3): 527-38.
[http://dx.doi.org/10.1016/j.bbrc.2004.11.059] [PMID: 15596132]
[4]
Liu X, Krawczyk E, Suprynowicz FA, et al. Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. Nat Protoc 2017; 12(2): 439-51.
[http://dx.doi.org/10.1038/nprot.2016.174] [PMID: 28125105]
[5]
Curry EL, Moad M, Robson CN, Heer R. Using induced pluripotent stem cells as a tool for modelling carcinogenesis. World J Stem Cells 2015; 7(2): 461-9.
[http://dx.doi.org/10.4252/wjsc.v7.i2.461] [PMID: 25815129]
[6]
Seki T, Fukuda K. Methods of induced pluripotent stem cells for clinical application. World J Stem Cells 2015; 7(1): 116-25.
[http://dx.doi.org/10.4252/wjsc.v7.i1.116] [PMID: 25621111]
[7]
Yuan H, Myers S, Wang J, et al. Use of reprogrammed cells to identify therapy for respiratory papillomatosis. N Engl J Med 2012; 367(13): 1220-7.
[http://dx.doi.org/10.1056/NEJMoa1203055] [PMID: 23013073]
[8]
Alkhilaiwi F, Paul S, Zhou D, et al. High-throughput screening identifies candidate drugs for the treatment of recurrent respiratory papillomatosis. Papillomavirus Res 2019; 8100181
[http://dx.doi.org/10.1016/j.pvr.2019.100181] [PMID: 31446060]
[9]
Ringer L, Sirajuddin P, Tricoli L, et al. The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. Oncotarget 2014; 5(21): 10678-91.
[http://dx.doi.org/10.18632/oncotarget.2528] [PMID: 25296977]
[10]
Kettunen K, Boström PJ, Lamminen T, et al. Personalized drug sensitivity screening for bladder cancer using conditionally reprogrammed patient-derived cells. Eur Urol 2019; 76(4): 430-4.
[http://dx.doi.org/10.1016/j.eururo.2019.06.016] [PMID: 31256944]
[11]
Timofeeva OA, Palechor-Ceron N, Li G, et al. Conditionally reprogrammed normal and primary tumor prostate epithelial cells: a novel patient-derived cell model for studies of human prostate cancer. Oncotarget 2017; 8(14): 22741-58.
[http://dx.doi.org/10.18632/oncotarget.13937] [PMID: 28009986]
[12]
Lai Y, Wei X, Lin S, Qin L, Cheng L, Li P. Current status and perspectives of patient-derived xenograft models in cancer research. J Hematol Oncol 2017; 10(1): 106.
[http://dx.doi.org/10.1186/s13045-017-0470-7] [PMID: 28499452]
[13]
Jin K, Teng L, Shen Y, He K, Xu Z, Li G. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol 2010; 12(7): 473-80.
[http://dx.doi.org/10.1007/s12094-010-0540-6] [PMID: 20615824]
[14]
Beglyarova N, Banina E, Zhou Y, et al. Screening of conditionally reprogrammed patient-derived carcinoma cells identifies ERCC3-MYC interactions as a target in pancreatic cancer. Clin Cancer Res 2016; 22(24): 6153-63.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-0149] [PMID: 27384421]
[15]
Borodovsky A, McQuiston TJ, Stetson D, et al. Generation of stable PDX derived cell lines using conditional reprogramming. Mol Cancer 2017; 16(1): 177.
[http://dx.doi.org/10.1186/s12943-017-0745-1] [PMID: 29212548]
[16]
Mondal AM, Ma AH, Li G, et al. Fidelity of a PDX-CR model for bladder cancer. Biochem Biophys Res Commun 2019; 517(1): 49-56.
[http://dx.doi.org/10.1016/j.bbrc.2019.06.165] [PMID: 31303270]
[17]
Sayej WN, Foster C, Jensen T, Chatfield S, Finck C. Expanding and characterizing esophageal epithelial cells obtained from children with eosinophilic esophagitis. Pediatr Res 2018; 84(2): 306-13.
[http://dx.doi.org/10.1038/s41390-018-0033-9] [PMID: 29895838]
[18]
Jensen TJ, Foster C, Sayej W, Finck CM. Conditional reprogramming of pediatric human esophageal epithelial cells for use in tissue engineering and disease investigation. J Vis Exp 2017; 121(121)e55243
[http://dx.doi.org/10.3791/55243] [PMID: 28362412]
[19]
Wolf S, Perez GF, Mukharesh L, et al. Conditional reprogramming of pediatric airway epithelial cells: A new human model to investigate early-life respiratory disorders. Pediatr Allergy Immunol 2017; 28(8): 810-7.
[http://dx.doi.org/10.1111/pai.12810] [PMID: 28981980]
[20]
Brewington JJ, Filbrandt ET, LaRosa FJ III, et al. Generation of human nasal epithelial cell spheroids for individualized cystic fibrosis transmembrane conductance regulator study. J Vis Exp 2018; 134(134)e57492
[http://dx.doi.org/10.3791/57492] [PMID: 29708545]
[21]
Peters-Hall JR, Coquelin ML, Torres MJ, et al. Long-term culture and cloning of primary human bronchial basal cells that maintain multipotent differentiation capacity and CFTR channel function. Am J Physiol Lung Cell Mol Physiol 2018; 315(2): L313-27.
[http://dx.doi.org/10.1152/ajplung.00355.2017] [PMID: 29722564]
[22]
Wang L, Ye L, Wei G, et al. Conditional reprogrammed human limbal epithelial cells represent a novel in vitro cell model for drug responses. Biochem Biophys Res Commun 2018; 499(4): 735-42.
[http://dx.doi.org/10.1016/j.bbrc.2018.03.168] [PMID: 29577905]
[23]
Moorefield EC, Blue RE, Quinney NL, Gentzsch M, Ding S. Generation of renewable mouse intestinal epithelial cell monolayers and organoids for functional analyses. BMC Cell Biol 2018; 19(1): 15.
[http://dx.doi.org/10.1186/s12860-018-0165-0] [PMID: 30111276]
[24]
Su S, Di Poto C, Kroemer AH, et al. Establishment of ornithine transcarbamylase deficiency-derived primary human hepatocyte with hepatic functions. Exp Cell Res 2019; 384(1)111621
[http://dx.doi.org/10.1016/j.yexcr.2019.111621] [PMID: 31513782]
[25]
Wang Z, Bi B, Song H, et al. Proliferation of human hepatocellular carcinoma cells from surgically resected specimens under conditionally reprogrammed culture. Mol Med Rep 2019; 19(6): 4623-30.
[http://dx.doi.org/10.3892/mmr.2019.10160] [PMID: 31059040]
[26]
Su S, Di Poto C, Roy R, et al. Highlight article: Long-term culture and characterization of patient-derived primary hepatocytes using conditional reprogramming. Exp Biol Med (Maywood) 2019; 244(11): 857-64.
[http://dx.doi.org/10.1177/1535370219855398] [PMID: 31184925]
[27]
Palechor-Ceron N, Suprynowicz FA, Upadhyay G, et al. Radiation induces diffusible feeder cell factor(s) that cooperate with ROCK inhibitor to conditionally reprogram and immortalize epithelial cells. Am J Pathol 2013; 183(6): 1862-70.
[http://dx.doi.org/10.1016/j.ajpath.2013.08.009] [PMID: 24096078]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 22
Year: 2020
Published on: 05 July, 2020
Page: [2657 - 2660]
Pages: 4
DOI: 10.2174/1381612826666200316155252
Price: $65

Article Metrics

PDF: 23
HTML: 3



Related Article(s)

Most Downloaded Article(s)